Ann: Opthea to Present at SVB Leerink Healthcare Conference, page-17

From all research and what's been presented by the business they are on a path, having invested a considerable amount, to delivering a much needed product into a large potential market.
OPT respectfully, needs the CEO not to be distracted by other corporate involvement, and also requires a concerted effort with investor relations and greater support from major shareholders.
Amazed to see how much cost and energy goes into a CR and then so little effort into preserving value for stakeholders. Upholding value in the business will eventually result in realising the full potential once all trials are completed and approvals achieved, which from all information provided by OPT is looking highly promising. At the right time with a go to market plan either on its own or disposal to a pharmaceutical major that will likely be the inflection point for significant value creation.
DYOR and good luck to those invested in what could turn out to be a substantial multi-bagger. Some posts on this forum even suggesting it could even be a 10 - 15X.